Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves.

Licensing 13

Licensing Depreciation Pharmaceuticals Budgeting 13

Harvard Business Review

DECEMBER 12, 2012

Based on data covering the period from 2005 to 2011, it charts how globalization has evolved since the onset of the financial crisis at the global, regional, and national levels. Capital markets are fragmenting and while merchandise trade recovered strongly since 2009, the intensity of services trade has remained stagnant.

Report 15

Report Merchandising GDP Globalization 15

Harvard Business Review

AUGUST 17, 2012

Cipla, an India-based producer of low cost antiretroviral drugs (ARVs) is one of the biggest success stories in the pharma industry. It has doubled its market cap in the five years and sales reached almost $1.5 and other traditionally developed markets. and other traditionally developed markets.

Company 11

Company Pharmaceuticals Business Model Fixed Costs 11

Harvard Business Review

NOVEMBER 8, 2017

With expanding middle classes demanding more-comprehensive care, governments of these emerging markets are under pressure to invest as chronic disease rates — particularly those related to Western lifestyles — dramatically increase and the average age of their once-young populations begins to rise. Insight Center.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. By the end of October in 2010, the market value of the 100 constituent stocks reached 582 billion RMB, accounting for 31% of the total market value of the Shanghai Stock Exchange's A shares. Stay tuned.

Long-term 14

Long-term Sample Report Pharmaceuticals 14

Harvard Business Review

FEBRUARY 24, 2015

The first category is exogenous factors over which the business has little control: the growth of the markets into which it sells; the competitive intensity and thus the average profitability of the industry in which it operates; or the fragmentation of its industry and thus the scope for a growth-by-acquisition approach.

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

JUNE 16, 2016

By the mid-1980’s, the American semiconductor industry seemed like it was doomed. So in 1986, the American government created SEMATECH , a consortium of government agencies, research institutions and private industry. To understand the nature of the problem, let’s look at how penicillin was brought to market.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

JUNE 29, 2015

Maybe you remember how savagely the industry was portrayed during the 2012 U.S. Amess, Stiebale, and Wright gathered information from three different databases—one on firm characteristics like sales and industry type, one on LBO deals, and one on patent applications and citations. that didn’t undergo buyouts.

LBO 8

LBO Innovation Sample Short-term 8

Harvard Business Review

DECEMBER 14, 2015

Mindfulness is quickly following yoga in becoming a billion-dollar industry. “There was this one instance where the market tanked and there was panic on the desk. Thanks to my meditation practice, I was able to keep my composure and propose solutions to reduce the impact of the market crash.” Patrick Pilz.

CEO 8

CEO Emotional Intelligence Cooper Pharmaceuticals 8

Strategy Driven

JANUARY 24, 2011

Closing the Execution Gap : How Great Leaders and Their Companies Get Results by Richard Lepsinger If an organization can’t execute its plans and initiatives, nothing else matters: not the most solid, well thought-out strategy, not the most innovative business model, not even technological breakthroughs that could transform an industry.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

NOVEMBER 2, 2018

Competing for scarce labor in a tight market, they will have trouble continuing to shift medical bills onto employees as they have for several decades. To address these challenges, they will have to band together in purchasing coalitions that give them the local market power to force health systems to reform. Tim Robberts/Getty Images.

Health Care 8

Health Care Cost Insurance Price 8

Harvard Business Review

NOVEMBER 20, 2015

Until a few years ago Steve Cronce’s Raphael Industries did $1 million dollars a year of specialized industrial painting for customers within driving distance of their plant in Milwaukee, Wisconsin. He is poised to become the leader in this segment of a multi-billion dollar market. I am no longer limited by geography.”

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

MAY 10, 2013

But such expectations are unrealistic in many industries. As noted management expert Geoffrey Moore told me with respect to high-velocity competition, "I''m not sure you ever want to be in the public markets." Its RAZR thin phone was a huge success in the mid-2000''s, and the market raved. Take Motorola, for instance.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

NOVEMBER 21, 2013

For many years, beginning in 1942, Premarin was the only hormone replacement therapy drug on the market derived from a natural source. Wyeth, a pharmaceutical acquired by Pfizer in 2009, was the sole supplier of Premarin. Why do some companies choose to patent their innovation while others choose to hide it? Such was not the case.

Intangible Assets 8

Intangible Assets Merchandising Innovation Pharmaceuticals 8

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. Although uncertainty is accelerating, it isn’t affecting all industries the same way. and technological uncertainty (can we make a desirable solution?) — and how much uncertainty your industry faces depends on the interaction of the two.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

MAY 25, 2017

The pipeline for new drugs is bursting, and new devices and tools in the rapidly emerging digital health space will come to market more quickly. Investors are already keenly focused on this area, with many startups competing for a slice of the market. A third growth area is in EHRs and digital health applications.

Health Care 9

Health Care Trends Venture Funding Technology 9